Breakthrough Therapy News Today

Of trying to be funny. They were more in Pushingpola A Political Agenda that was neve i wasr as comfortableeded with comedy, where i needed to make a point about somethin t. So i always thought that that when trump came alonhg ,what a lot of people have to revert to is, doesnt he. I hate that guy. And those arent jokes. And so i think its just, uto you know, im really going Out On A Limb here saying that his Greatestre Sayin now is that hei think hes hurt political comedy by being so outlandish ...

Of trying to be funny, they were more interested in pushing a political agenda. I was never as comfortable with comedy where i needed to make a point about something, so i always thought that when trump came along, what a lot of people have to revert to is, doesnt he saw . I hate that guy. [bleep]. And those arent jokes. So i think it is just, you know, im really going Out On A Limb here saying that is his greatest crime. [laughs] i think he has hurt political comedy by being so outlandish himse...

One of the stocks to benefit the most from the artificial intelligence (AI) craze has been Super Micro Computer (Nasdaq: SMCI). Before AI took over, Super Micro flew under the radar of many investors, blending into the technology landscape with its servers. But with the rise of AI, it turns out Super Micro Computer is […]

03.06.2024 - MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) - Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and ... Seite 1

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application

TAK-861 demonstrated significant and sustained improvements in the treatment of narcolepsy type 1 in a phase 2b clinical trial.

MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has...

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,...

Novartis presented positive results from the ASC4FIRST trial at the ASCO 2024 meeting. The trial showed that Scemblix, a drug to treat chronic myeloid leukemia, achieved higher major molecular...

The designation is supported by data from the phase 2b ORIGIN trial.